From a therapeutic point of view, targeting of FcγR-TLR cross-talk to restore the anti-inflammatory function of M2 macrophages may be a valuable tool to attenuate inflammation in IgG immune complex-associated diseases such as RA, systemic sclerosis and systemic lupus erythematosus. This evidence concerns the gene FCGR2A and systemic sclerosis.